These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 10524422)

  • 1. The influence of the boost in breast-conserving therapy on cosmetic outcome in the EORTC "boost versus no boost" trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer.
    Vrieling C; Collette L; Fourquet A; Hoogenraad WJ; Horiot JC; Jager JJ; Pierart M; Poortmans PM; Struikmans H; Van der Hulst M; Van der Schueren E; Bartelink H
    Int J Radiat Oncol Biol Phys; 1999 Oct; 45(3):677-85. PubMed ID: 10524422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Objective Measurement of Cosmetic Outcomes of Breast Conserving Therapy Using BCCT.core.
    Yu T; Eom KY; Jang NY; Kim KS; Koo TR; Kwon J; Kim BH; Kang E; Kim SW; Kim JS; Kim IA
    Cancer Res Treat; 2016 Apr; 48(2):491-8. PubMed ID: 26130667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal cosmetic outcome after planned IORT boost with low kV X-rays-monocentric results from the TARGIT BQR registry.
    Goerdt L; Poemsl J; Spaich S; Welzel G; Abo-Madyan Y; Ehmann M; Berlit S; Tuschy B; Sütterlin M; Wenz F; Sperk E
    Transl Cancer Res; 2023 Jul; 12(7):1715-1726. PubMed ID: 37588731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Radiotherapy Volumes on Late-Term Cosmetic Outcomes and Quality of Life in Patients With Unifocal and Multifocal/Multicentric Breast Cancer After Breast-Conserving Surgery.
    Altınok P; Tekçe E; Kızıltan HŞ; Gücin Z; Mayadağlı A
    Eur J Breast Health; 2023 Oct; 19(4):287-296. PubMed ID: 37795008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Panel calls for giant boost to space station research.
    Greshko M
    Science; 2023 Sep; 381(6663):1144-1145. PubMed ID: 37708277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial.
    Bartelink H; Horiot JC; Poortmans PM; Struikmans H; Van den Bogaert W; Fourquet A; Jager JJ; Hoogenraad WJ; Oei SB; Wárlám-Rodenhuis CC; Pierart M; Collette L
    J Clin Oncol; 2007 Aug; 25(22):3259-65. PubMed ID: 17577015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial.
    Bartelink H; Maingon P; Poortmans P; Weltens C; Fourquet A; Jager J; Schinagl D; Oei B; Rodenhuis C; Horiot JC; Struikmans H; Van Limbergen E; Kirova Y; Elkhuizen P; Bongartz R; Miralbell R; Morgan D; Dubois JB; Remouchamps V; Mirimanoff RO; Collette S; Collette L;
    Lancet Oncol; 2015 Jan; 16(1):47-56. PubMed ID: 25500422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation.
    Bartelink H; Horiot JC; Poortmans P; Struikmans H; Van den Bogaert W; Barillot I; Fourquet A; Borger J; Jager J; Hoogenraad W; Collette L; Pierart M;
    N Engl J Med; 2001 Nov; 345(19):1378-87. PubMed ID: 11794170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the boost dose of 10 Gy versus 26 Gy in patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10-year results of the randomised EORTC boost trial.
    Poortmans PM; Collette L; Horiot JC; Van den Bogaert WF; Fourquet A; Kuten A; Noordijk EM; Hoogenraad W; Mirimanoff RO; Pierart M; Van Limbergen E; Bartelink H;
    Radiother Oncol; 2009 Jan; 90(1):80-5. PubMed ID: 18707785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France.
    Romestaing P; Lehingue Y; Carrie C; Coquard R; Montbarbon X; Ardiet JM; Mamelle N; Gérard JP
    J Clin Oncol; 1997 Mar; 15(3):963-8. PubMed ID: 9060534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial.
    Vrieling C; van Werkhoven E; Maingon P; Poortmans P; Weltens C; Fourquet A; Schinagl D; Oei B; Rodenhuis CC; Horiot JC; Struikmans H; Van Limbergen E; Kirova Y; Elkhuizen P; Bongartz R; Miralbell R; Morgan DA; Dubois JB; Remouchamps V; Mirimanoff RO; Hart G; Collette S; Collette L; Bartelink H;
    JAMA Oncol; 2017 Jan; 3(1):42-48. PubMed ID: 27607734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of adverse events in partial- or whole breast radiotherapy: investigation of cosmesis, toxicities and quality of life in a meta-analysis of randomized trials.
    Haussmann J; Budach W; Corradini S; Krug D; Jazmati D; Tamaskovics B; Bölke E; Pedotoa A; Kammers K; Matuschek C
    Radiat Oncol; 2023 Nov; 18(1):181. PubMed ID: 37919752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultrasonographic Evaluation of Skin Toxicity Following Radiotherapy of Breast Cancer: A Systematic Review.
    Hussein FA; Manan HA; Mustapha AWMM; Sidek K; Yahya N
    Int J Environ Res Public Health; 2022 Oct; 19(20):. PubMed ID: 36294025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Boost and hypofractionation in DCIS].
    Dunst J; Krug D
    Strahlenther Onkol; 2022 Dec; 198(12):1122-1124. PubMed ID: 36264356
    [No Abstract]   [Full Text] [Related]  

  • 15. Early Outcome, Cosmetic Result and Tolerability of an IOERT-Boost Prior to Adjuvant Whole-Breast Irradiation.
    Jazmati D; Bölke E; Halfmann K; Tamaskovics B; Ruckhäberle E; Fehm T; Hoffmann J; Krug D; Nestle Krämling C; Corradini S; Budach W; Mohrmann S; Haussmann J; Matuschek C
    Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35892894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methods of Esthetic Assessment after Adjuvant Whole-Breast Radiotherapy in Breast Cancer Patients: Evaluation of the BCCT.core Software and Patients' and Physicians' Assessment from the Randomized IMRT-MC2 Trial.
    Forster T; Köhler C; Dorn M; Häfner MF; Arians N; König L; Harrabi SB; Schlampp I; Meixner E; Heinrich V; Weidner N; Golatta M; Hennigs A; Heil J; Hof H; Krug D; Debus J; Hörner-Rieber J
    Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Outcomes of an International Cooperative Study of Intraoperative Radiotherapy Upfront Boost With Low Energy X-Rays in Breast Cancer.
    Sarria GR; Ramos ML; Palacios A; Del Castillo R; Castro F; Calvo A; Cotrina JM; Heredia A; Galarreta JA; Fuentes-Rivera P; Avalos A; Martinez DA; Colqui K; Ziegler G; Schmeel LC; Pinillos LV; Wenz F; Giordano FA; Sarria GJ; Sperk E
    Front Oncol; 2022; 12():850351. PubMed ID: 35371998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Automated hybrid volumetric modulated arc therapy (HVMAT) for whole-breast irradiation with simultaneous integrated boost to lumpectomy area : A treatment planning study.
    Cilla S; Romano C; Macchia G; Boccardi M; De Vivo LP; Morabito VE; Buwenge M; Strigari L; Indovina L; Valentini V; Deodato F; Morganti AG
    Strahlenther Onkol; 2022 Mar; 198(3):254-267. PubMed ID: 34767044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are 5-Year Randomized Clinical Trial Results Sufficient for Implementation of Short-Course Whole Breast Radiation Therapy?
    Gillespie EF; Khan AJ; Cahlon O; Braunstein LZ
    Pract Radiat Oncol; 2021; 11(5):301-304. PubMed ID: 34479656
    [No Abstract]   [Full Text] [Related]  

  • 20. The Acute and Late Toxicities of MRI-Guided External Beam Partial Breast Irradiation Delivered Using a Once-Per-Day Regimen.
    Lee HI; Kim K; Kim JH; Chang JH; Shin KH
    Front Oncol; 2021; 11():649301. PubMed ID: 33833998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.